Do FBT and IDNA hold the same stocks?

By their latest filings, 22% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, FBT or IDNA?

FBT has 25% of its weight in S&P 500 names and IDNA has 27%, so FBT differs more from the index.

Which is cheaper, FBT or IDNA?

FBT charges 0.55% a year and IDNA charges 0.47%, so IDNA is cheaper. Fees come from each fund's prospectus.

Data as of Nov 4, 2026.

Thematic ETFs

FBT vs IDNA: Holdings Overlap & Returns

Share on X Download as PDF

Over the year to Nov 4, 2026, FBT returned +47.0% to IDNA's +81.1%; 22% of their weight is in the same names.

askIQ about this page

askIQ about FBT and IDNA

Net assets on Nov 3, 2026: $3.1bn for First Trust NYSE Arca Biotechnology Index Fund and $340m for iShares Genomics Immunology and Healthcare ETF.

FBT on its own →IDNA on its own →

At a glance

24.8%

FBT in the S&P 500

27.4%

IDNA in the S&P 500

+47.0%

FBT total return, 1 year

+81.1%

IDNA total return, 1 year

FBT · 1 year to Nov 4, 2026 75% of its weight is outside the S&P 500

25% of FBT's weight is in S&P 500 companies and 75% is outside the index. Holdings as of Nov 3, 2026.

IDNA · 1 year to Nov 4, 2026 73% of its weight is outside the S&P 500

27% of IDNA's weight is in S&P 500 companies and 73% is outside the index. Holdings as of Nov 3, 2026.

Pair scorecard

IDNA costs 0.08 points a year less; their one-year returns differ by 34.1 points; FBT is 9.1 times larger.

FBT vs IDNA: Holdings Overlap & Returns
Measure	FBT	IDNA
Return
Measure	FBT	IDNA
Total return, 1 year	+47.0%	+81.1%
Drawdown
Measure	FBT	IDNA
Below its all-time high		16.5%, high on Sep 2, 2021
Benchmark
Measure	FBT	IDNA
What it tracks	Biotech	Genomics and gene editing
Cost and size
Measure	FBT	IDNA
Expense ratio	0.55%	0.47%
Net assets, as of Nov 3, 2026	$3.1bn	$340m
Holdings
Measure	FBT	IDNA
Holdings in common	22%

Method

Risk and return

Jun 21, 2019 to Oct 30, 2026 · 384 weekly returns

FBT IDNA

Return

Total return edge FBT +103.1% +69.5%

Annualized edge FBT +10.1% +7.4%

Price return edge FBT +99.0% +59.6%

Risk

Volatility edge FBT 21.9% 30.1%

Max drawdown edge FBT −29.0% −68.1%

Risk-adjusted

Sharpe edge FBT 0.42 0.29

Sortino edge FBT 0.62 0.44

Calmar edge FBT 0.35 0.11

Reading

From Jun 2019 to Oct 2026, FBT returned more: +103.1% to +69.5%. FBT swung less: 21.9% to 30.1%. FBT fell less at its worst: −29.0% to −68.1%.

Full scorecard

9 measures, with how each is measured Open ↓

Risk and return: FBT vs IDNA: Holdings Overlap & Returns
Measure	FBT	IDNA	Edge	How it is measured
Return
Total return	+103.1%	+69.5%	FBT	Price change plus distributions, reinvested.
Annualized	+10.1%	+7.4%	FBT	Total return as a yearly rate.
Price return	+99.0%	+59.6%	FBT	Price change alone, distributions left out.
Risk
Volatility	21.9%	30.1%	FBT	Spread of weekly returns, annualized. Lower is steadier.
Downside deviation	14.7%	20.2%	FBT	Like volatility, counting only weeks below the Treasury bill rate.
Max drawdown	−29.0%	−68.1%	FBT	Deepest fall from a high to the low after it.
Risk-adjusted
Sharpe	0.42	0.29	FBT	Return above Treasury bills per unit of volatility.
Sortino	0.62	0.44	FBT	Return above Treasury bills per unit of downside deviation.
Calmar	0.35	0.11	FBT	Annualized return divided by the max drawdown.

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 384 weekly returns. Cash rate: the 13-week Treasury bill.

What they share

22%

By the books each fund has filed, FBT and IDNA hold 22% of their money in the same securities at the same weight. Holdings dated Nov 3, 2026.

50%

0 half 100%

half

22% in common

Positions both hold · largest shared weight first FBT IDNA

Genmab A/S (ADR) 4.81% 6.26%

Regeneron Pharmaceuticals, Inc. 4.18% 4.24%

Exelixis, Inc. 3.88% 3.80%

Vertex Pharmaceuticals Incorporated 3.34% 3.29%

Incyte Corporation 3.35% 3.18%

BioNTech SE (ADR) 2.88% 2.73%

Only in one fund ↓

Only in FBT

Halozyme Therapeutics, Inc. 3.74%

Neurocrine Biosciences, Inc. 3.71%

Alkermes Plc 3.61%

Amgen Inc. 3.57%

Veracyte, Inc. 3.57%

Gilead Sciences, Inc. 3.56%

Biogen Inc. 3.54%

TG Therapeutics, Inc. 3.52%

Only in IDNA

MODERNA 13.33%

TWIST BIOSCIENCE 5.61%

BAYER AG 3.85%

TAKEDA PHARMACEUTICAL 3.77%

REVOLUTION MEDICINES 3.60%

CARIS LIFE SCIENCES 3.50%

MERCK & CO INC 3.32%

ROCHE PS PAR AG 3.20%

Check overlap with more funds →

Window by window

Window by window: FBT vs IDNA: Holdings Overlap & Returns
	Total return
Window	FBT	IDNA
3 months	+12.2%	+32.4%
6 months	+30.5%	+45.6%
1 year	+47.0%	+81.1%
3 years	+100.5%	+134.8%
Since launchNot the same days: FBT Jun 2006 · IDNA Jun 2019	+1,349.5%	+88.1%

Open this comparison in the app →

Side by side

FBT First Trust NYSE Arca Biotechnology Index Fund · Holds 30 stocks in biotech, 25% of its weight in S&P 500 companies IDNA iShares Genomics Immunology and Healthcare ETF · Holds 52 stocks in genomics and gene editing, 27% of its weight in S&P 500 companies

Issuer First Trust iShares

Theme Biotech Genomics and gene editing

In the S&P 500 24.8% 27.4%

Active share vs the S&P 500 99.1% 99.1%

In the Nasdaq-100 16.9% 7.5%

Holdings 30 52

Top ten, share of the fund 38.2% 51.3%

Expense ratio 0.55% 0.47%

Fee for the differing part 0.55% 0.47%

Total return, 1 year +47.0% +81.1%

vs its benchmark not measured not measured

Below its high −0.3% −16.5%

Net assets, as of Nov 3, 2026 $3.1bn $340m

As of Nov 4, 2026. Source: ETFIQ.

22% of the two portfolios are the same securities at the same weight.

Client brief:

The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.

Your saved page · Privacy.

Alert

About each fund

FBT

By weight, 25% of FBT's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 38% of the fund across 30 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +47.0% with distributions reinvested.

IDNA

By weight, 27% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 51% of the fund across 52 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +81.1% with distributions reinvested. It sits 16.5% below its all-time high of Sep 2, 2021.

Questions people ask

Do FBT and IDNA hold the same stocks?: By their latest filings, 22% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, FBT or IDNA?: FBT has 25% of its weight in S&P 500 names and IDNA has 27%, so FBT differs more from the index.
Which is cheaper, FBT or IDNA?: FBT charges 0.55% a year and IDNA charges 0.47%, so IDNA is cheaper. Fees come from each fund's prospectus.

Other comparisons

FBT vs GNOM FBT vs GNMX FBT vs ARKG FBT vs IBBQ IDNA vs PBPH IDNA vs XBI IDNA vs IBB IDNA vs PBE

Where to next

All thematic ETFs ranked by the S&P 500 Difference Score →How the scores are computed →FBT on its own →IDNA on its own →FBT dividend history →FBT holdings →IDNA dividend history →IDNA holdings →Method →Standards and sources →

Sources and dates

FBT filings on SEC EDGAR ↗

FBT prospectus with the expense ratio (SEC) ↗

First Trust page for FBT ↗

IDNA filings on SEC EDGAR ↗

IDNA prospectus with the expense ratio (SEC) ↗

iShares page for IDNA ↗

Links are sources, not endorsements. A comparison is not a recommendation.

How this is computed

Overlap adds up the smaller of the two weights for each security both funds hold.

Every number is an ETFIQ calculation with distributions reinvested.

Cite this pageCitation, APA and Markdown

ETFIQ, FBT against IDNA, data as of Nov 4, 2026. https://etfiq.com/compare/themes/fbt-vs-idna

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.